Genfit SA  

(Public, EPA:GNFT)   Watch this stock  
Find more results for EPA:ALGFT
36.20
-0.29 (-0.81%)
Real-time:   4:29PM GMT+2
EPA real-time data - Disclaimer
Currency in EUR
Range 36.00 - 36.45
52 week 24.61 - 70.64
Open 36.15
Vol / Avg. 86,744.00/179,551.00
Mkt cap 867.27M
P/E     -
Div/yield     -
EPS -0.77
Shares 23.96M
Beta     -
Inst. own     -
Jun 3, 2015
Genfit SA Annual Shareholders Meeting
May 7, 2015
Genfit SA at Deutsche Bank Health Care Conference
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -246.37% -251.27%
Operating margin -252.36% -254.71%
EBITD margin - -250.56%
Return on average assets -19.25% -29.48%
Return on average equity -24.63% -40.29%
Employees 81 -
CDP Score - -

Address

Parc Eurasante 885, Avenue Eugene Avinee
LOOS, 59120
France
+33-3-20164000 (Phone)
+33-3-20164001 (Fax)

Website links

Description

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company’s research programs develop diversified pipeline of drug candidates, including GFT505, which completes a Phase 2b study in NASH. The Company’s facilities are located in France and the United States. The Company’s wholly owned subsidiaries include Genfit Corporation, located in Cambridge, the United States and Genfit Pharmaceuticals SAS.

Officers and directors

Xavier Guille Des Buttes Chairman of the Supervisory Board
Jean-Francois Mouney Chairman of the Management Board, Chief Executive Officer
Charles Woler Vice Chairman of the Supervisory Board
Raphael Darteil Chief Operating Officer, Executive Vice President, Member of the Management Board
Nathalie Huitorel Executive Vice President of Finance, Member of the Management Board
Bart Staels President of the Scientific Advisory Board, Member of the Management Board
Frederic Lobez Member of the Supervisory Board, Representative of Universite de Lille II
Philippe Moons Member of the Supervisory Board, Representative of Finorpa
Florence Sejourne Member of the Supervisory Board, Representative of Biotech Avenir
Philippe Traisnel MBA Independent Supervisory Board, Representative of CM-CIC Capital Finance